HUAKESO@EC2608A

UNI HEALTH

QUANTGROUP

AE LOGISTICS

XUNCE

KINTOR PHARMA-B

XunZhong

ILUVATAR COREX

HP LIVING TECH

NANFANG COMM

ZHAOWEI

06869

00100

02513

09926

06809

02600

00857

01898

02714

01088

YOFC(06869) rose 24.33%, with a trading turnover 6.9 Billion HKD, and a year-to-date rose 242%. MINIMAX-WP(00100) rose 22.37%, with a trading turnover 4.3 Billion HKD, and a year-to-date rose 639.4%. CHALCO(02600) fell 3.58%, with a trading turnover 754.5 Million HKD, and a year-to-date rose 8.4%. PETROCHINA(00857) fell 3.57%, with a trading turnover 2.3 Billion HKD, and a year-to-date rose 22.4%.

Top Gainers & Losers

YOFC

MINIMAX-WP

KNOWLEDGE ATLAS

AKESO

MONTAGE TECH

CHALCO

PETROCHINA

CHINA COAL

MUYUAN

CHINA SHENHUA

Top 5 HK Stock Gainers/Losers (>100B) (3.10)

AKESO rose 10.90%; Innovent Biologics rose 3.79%, with a transaction volume of HKD 404 million; 3SBio rose 5.48%, with a transaction volume of HKD 352 million; BeiGene rose 2.63%, with a transaction volume of HKD 309 million; Kelun-Bio rose 7.37%, with a market value of HKD 95.1 billion

HK Stock Movers Tracker

Hong Kong Stock Movement: AKESO's tri-specific antibody approved for clinical trials, stock price surges over 10%, attracting market attention

560600

520690

159892

512290

516820

159837

159102

159316

159992

510660

516930

588250

159859

520880

588860

588130

512010

Jiahui International Cancer Center (JICC) in China has successfully stabilized a U.S. patient with advanced non-small cell lung cancer (NSCLC) using ivonescimab, a novel immunotherapy. The patient, who had previously exhausted all standard treatments, received care from a multidisciplinary team, including U.S.-trained oncologists. Despite developing complications requiring ICU care, the patient's condition has stabilized. JICC is gaining recognition as a global hub for advanced cancer care, attracting patients from around the world.

prnewswire

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Guotai CSI Bio-medicine ETF

Ping An CSI Medicine and Medical Device Innovation ETF

China Merchants CSI Biotechnology Theme ETF

E Fund CSI Biotechnology Theme ETF

Huaan Hang Seng Biotech ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

E Fund Hang Seng SCHK Innovative Drug ETF

ChinaAMC CSI Biotechnology Theme ETF

Yinhua CSI Innovative Drugs Industry ETF

ChinaAMC SSE Health Care ETF Initiating Fund

China Southern Hang Seng Biotech ETF(QDII)

Bosera Hang Seng Health Care ETF(QDII)

Minsheng Royal CSI Biotechnology Theme ETF

Penghua SSE STAR Biology and Medicine ETF

Tianhong CNI BIOMEDICINE ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

ICBCCS SSE STAR Biology and Medicine ETF

ChinaAMC SSE STAR Biology and Medicine ETF

E Fund CSI 300 Health Care ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

23:20 ETU.S. Patient with Advanced Lung Cancer Stabilized by Novel Immunotherapy Treatment in China

09618

09896

09988

On March 6th, the Hong Kong stock market's risk appetite warmed up, with all three major indices strengthening, led by the Hang Seng Tech Index which rose by 3.15%. The retail and internet sectors showed strong momentum, with JD-SW leading the surge with a 9.95% increase, while Tencent Holdings had the highest trading volume and closed up by 3.39%. On the macro level, the rebound in PMI and the recovery in exports provided support for the fundamentals. Although the rebound momentum continues, the market is still focused on whether policies and liquidity can help break through previous highs

- The Hong Kong stock market saw overall gains, with the Hang Seng Index closing at 25,757.29 points, up by 1.72%.  
- Notable performances included JD.com surging 9.95% and Tencent gaining 3.39%, while mixed results emerged in specific sectors.  
- Market momentum is supported by improvements in macroeconomic indicators, driving investor confidence and attention towards future policy impacts on risk preferences.

Market Heartbeat

JD-SW

MNSO

BABA-W

TENCENT

KUAISHOU-W

BILIBILI-W

XIAOMI-W

LENOVO GROUP

LEGENDHOLDING

REMEGEN

MENGNIU DAIRY

CH ENERGY ENG

CHINA RES LAND

Tencent

Tencent Holdings Limited

Hang Seng TECH Index

Hong Kong stocks close | The Science and Technology Index leads with a 3.15% increase, JD rises nearly 10%, and both Tencent and Alibaba rise over 3%

Nomura Adjusts Akeso's Price Target to HK$112.73 From HK$120.64, Keeps at Neutral

marketscreener

Nomura Adjusts Akeso's Price Target to HK$112.73 From HK$120.64, Keeps at Neutral

Akeso, Inc. announced that cadonilimab achieved a 100% 24-month overall survival (OS) rate in patients with recurrent or metastatic cervical cancer who had a complete response in a Phase II study. The study, presented at the ESGO 2026 Congress, showed significant long-term survival benefits, with a median progression-free survival (PFS) rate of 84.6%. Cadonilimab, a bispecific antibody, is approved for multiple indications in China and is under evaluation in various Phase III trials globally. The findings highlight its potential as a new therapeutic option for advanced cervical cancer.

MorningStar

Cadonilimab Achieves 100% 24-Month OS in Complete Responders in R/M Cervical Cancer Based on Long-Term Phase II Results

Nomura has lowered the target price for AKESO to RMB 112.73, maintaining a "Neutral" rating. It is expected that the company's revenue last year reached RMB 3.3 billion, in line with market expectations, mainly driven by drug sales in the second half of the year. The gross margin improved to 82.1%, operating expenses were flat, and net profit was RMB 38 million, below expectations. It is projected that revenue for the fiscal year 2026 will reach RMB 5.3 billion, with a gross margin of 84.5% and net profit of RMB 954 million, exceeding expectations. Revenue forecasts have been revised down by 2% and 5%, respectively

AASTOCKS

Nomura lowers the target price of AKESO to 112.73 yuan with a rating of "Neutral"

As of the close on March 4th, the stock price continued to hover near the lower edge, with several attempts to test buying interest during the day but lacking sufficient strength, resulting in a weak rhythm. The funding situation appears more cautious, with not many proactive sell orders, but the buying support is also average, leading the market to choose to "wait and see." In the short term, it remains below the key level, with frequent actions to test support, and while there was a momentary rebound in intraday trading, its sustainability was insufficient. Technically, the price is not far from the lower edge, which is commonly viewed as a phase for testing support. If there is a rapid rebound in the morning session, it could easily trigger emotional fluctuations. Right-side trading pays more attention to the continuity of signals, as a single upward movement is unlikely to change the weak tone. 

A unique observation is that last week, the overseas biomedical index experienced an overall pullback, and rising interest rate expectations led to valuation compression, which spilled over into the Hong Kong innovative drug sector. This external shock, combined with a local news vacuum, has caused funds within the sector to lean towards more stable cash flow varieties, amplifying the volatility of AKESO. On the market front, sub-sectors within pharmaceuticals that have stronger defensive attributes have shown relative resilience, while buying interest in innovative drug targets is more selective regarding price levels, showing a rhythm of "low-point testing and upward probing." 

From a technical assistance perspective, the densely traded area at the near end still constitutes short-term pressure, and breaking above and stabilizing is usually interpreted by the market as a signal for rhythm switching. If the trading volume warms up in the morning session and the 5/10-day moving averages form a turning point and complete a price reversal, the quality of the rebound is expected to improve; conversely, if volume and price do not align, it may continue to hover near the lower edge, prolonging the bottoming process. It is important to be cautious that if there is another drop in the morning session that breaks through the support zone, the weakness may continue, and existing funds may further reduce risk exposure, shifting the trading focus downward

Technical Forecast

Morning Trend | AKESO (9926.HK) Retraces to Support, Is a Rebound Window Coming?

A partnership has been formed to assess the effectiveness of Akeso's cadonilimab with INOVIO's INO-5412 (comprising INO-5401 and INO-9012) in treating glioblastoma (GBM), a highly prevalent and aggressive type of brain cancer. This innovative treatment combination will undergo investigation in a Phase II adaptive trial.

Unusual Whales

Health Care Select Sector SPDR

VanEck Biotech ETF

Inovio Pharma

VG Health

iShares US Pharma

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

SPDR S&P Biotech

Ark Genomic Revolution ETF

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

iShares Global Healthcare

Akeso and INOVIO team up for Phase II trial on combination therapy for glioblastoma; promising potential treatment.

INOVIO and Akeso have announced a clinical collaboration to evaluate INO-5412, a DNA immunotherapy, in combination with Akeso's cadonilimab for treating glioblastoma (GBM). This collaboration will be part of the INSIGhT Phase 2 trial, aiming to find new treatments for GBM. The trial is set to begin dosing in the second half of 2026. The combination therapy builds on previous positive results and aims to enhance patient outcomes by providing additional checkpoint inhibition. Both companies will support the study, which is sponsored by the Dana-Farber Cancer Institute.

StockTitan

INOVIO and Akeso Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM) | INO Stock News

HeYu-B announced its 2025 annual performance, with revenue of 612 million RMB, an increase of 21.5% year-on-year. It recorded a net profit of 55.25 million RMB, a growth of 95.2%, with earnings per share of 0.09 RMB. No final dividend is declared

"Performance" and Yu's annual net profit of 55.25 million RMB increased by 95.2% with no dividend distribution

The Hang Seng Index opened higher, refreshing its nearly four-year high; Tencent's performance exceeded expectations, receiving collective bullish calls from major banks; Chip stocks strengthened on the logic of domestic substitution, with SMIC leading the gains; Ping An's stake increase in China Taiping H-shares ignited the insurance sector; Cryptocurrency concept stocks surged as Bitcoin hit a new high; In the pharmaceutical sector, Jingtai Holdings reported its first profit, rising over 11%, while East Buy saw a sudden 12% increase.

TENCENT-R

Tencent HK SDR 10to1

Ping An Insurance

PING AN

PING AN-R

Ping An Ins HK SDR2to1

Ping An

SMIC

SMIC HK SDR 5to1

CPIC

CHINA TAIPING

SUNSHINE INS

Life and Health Insurance

RemeGen

WUXI BIO

WuXi Biologics

BEONE MEDICINES

BeOne Medicines

Beigene

FI2 CSOP HSI

HUA HONG SEMI

Hua Hong

INNOCARE

InnoCare Pharma

GRANDSHORES

HORIZONROBOT-W

ZA ONLINE

SINOHOPE TECH

GUOTAI JUNAN I

XTALPI

Life Sciences Tools and Services

XL2CSOPHSTECH

Semiconductors

FL2 CSOP HSI

LINEKONG

INNOVENT BIO

OKG TECH

Interactive Media and Services

CSOP HS TECH

XI2CSOPHSTECH

EAST BUY

Hot Trades in Hong Kong Stocks (8.14) | Hang Seng Index Hits Four-Year High at Opening, Morgan Stanley Says Foreign Capital Accelerated Inflows into Chinese Stock Market in July

Another day where biotech stocks stand out in the Hong Kong market $AKESO(09926.HK) sold too early, lacking vision.

In my Hong Kong stock watchlist, it's another day for innovative drugs. $AKESO(09926.HK) was sold too soon, missing a 40% gain.

Hong Kong stocks' innovative medicine sector surges 66%, three-pronged approach ignites the golden track

WUXI APPTEC

WuXi AppTec

3SBIO

DUALITYBIO-B

HENGRUI PHARMA

Hengrui Pharma

JOINN

Hong Kong stocks' innovative drugs surge 66%! Three major catalysts ignite the 'golden track', can we still get on board in the second half of the year?

On July 11, the three major stock indices in Hong Kong rose together. In terms of sectors, technology stocks rose collectively, and securities and brokerage stocks mostly increased.

LAOPU GOLD

POP MART

MIXUE GROUP

GUMING

AIA Group

LIANLIAN

OSL GROUP

PICC P&C

MAO GEPING

BLOKS

CITIC SEC

The Hang Seng Index is approaching its highest level in nearly 3 years, with Chinese brokerage, insurance, and stablecoin concept stocks remaining hot!

HUAKESO@EC2608A(26813.HK)

Top 5 HK Stock Gainers/Losers (>100B) (3.10)

Hong Kong Stock Movement: AKESO's tri-specific antibody approved for clinical trials, stock price surges over 10%, attracting market attention

23:20 ETU.S. Patient with Advanced Lung Cancer Stabilized by Novel Immunotherapy Treatment in China

Hong Kong stocks close | The Science and Technology Index leads with a 3.15% increase, JD rises nearly 10%, and both Tencent and Alibaba rise over 3%

Nomura Adjusts Akeso's Price Target to HK$112.73 From HK$120.64, Keeps at Neutral